Abstract
The incidence of invasive fungal disease (IFD) is high in patients with hematological malignancies, including those with acute myeloid leukemia(AML)/myelodysplastic syndrome(MDS), and those receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). IFD is an important prognostic factor in patients with hematological malignancies. IFD is difficult to diagnose, and the efficacy of treatment is poor. Therefore, antifungal treatment begins with prevention. At present, there are still controversies about the clinical indications, drugs, administration time and efficacy of IFD chemoprevention. This article intends to review the research progress on the epidemiology and risk factors of IFD, as well as the clinical outcomes of antifungal agents for antifungal prophylaxis in patients with hematological malignancies. Key words: Antifungal agents; Hematologic neoplasms; Epidemiologic studies; Chemoprevention; Invasive fungal disease
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
